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Abbreviations:	BCA,	bicinchoninic	acid;	CV,	coefficient	of	variation;	MTT,	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium	 bromide;	 PBMCs,	 peripheral	 blood	 mononuclear	 cells;	 RPPA,	reverse	 phase	 protein	 array;	 SSMD,	 strictly	 standardised	 mean	 difference;	 TNFR1,	 tumour	necrosis	factor	receptor-1;	TRAPS,	TNF	receptor	associated	periodic	syndrome;	WT,	wild	type.		 	
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ABSTRACT:	TNF	Receptor	Associated	Periodic	Syndrome	(TRAPS)	is	an	autoinflammatory	disease	caused	by	mutations	in	TNF	Receptor	1	(TNFR1).		Current	therapies	for	TRAPS	are	limited	and	do	not	target	the	pro-inflammatory	signalling	pathways	that	are	central	to	the	disease	mechanism.		Our	aim	was	to	identify	drugs	for	repurposing	as	anti-inflammatories	based	on	their	ability	to	down-regulate	molecules	associated	with	inflammatory	signalling	pathways	that	are	activated	in	TRAPS.		This	was	achieved	using	rigorously	optimised,	high	through-put	cell	culture	and	reverse	phase	protein	microarray	systems	to	screen	compounds	for	their	effects	on	the	TRAPS-associated	inflammatory	signalome.		1360	approved,	publically	available,	pharmacologically	active	substances	were	investigated	for	their	effects	on	40	signalling	molecules	associated	with	pro-inflammatory	signalling	pathways	that	are	constitutively	upregulated	in	TRAPS.		The	drugs	were	screened	at	four	ten-fold	concentrations	on	cell	lines	expressing	both	wild-type	(WT)	TNFR1	and	TRAPS-associated	C33Y	mutant	TNFR1,	or	WT	TNFR1	alone;	signalling	molecule	levels	were	then	determined	in	cell	lysates	by	the	reverse-phase	protein	microarray.		A	novel	mathematical	methodology	was	developed	to	rank	the	compounds	for	their	ability	to	reduce	the	expression	of	signalling	molecules	in	the	C33Y-TNFR1	transfectants	towards	the	level	seen	in	the	WT-TNFR1	transfectants.	Seven	high-ranking	drugs	were	selected	and	tested	by	RPPA	for	effects	on	the	same	40	signalling	molecules	in	lysates	of	peripheral	blood	mononuclear	cells	(PBMCs)	from	C33Y-TRAPS	patients	compared	to	PBMCs	from	normal	controls.	The	fluoroquinolone	antibiotic	lomefloxacin,	as	well	as	others	from	this	class	of	compounds,	showed	the	most	significant	effects	on	multiple	pro-inflammatory	signalling	pathways	that	are	constitutively	activated	in	TRAPS;	lomefloxacin	dose-dependently	significantly	reduced	expression	of	7/40	signalling	molecules	across	the	Jak/Stat,	MAPK,	NF-kB	and	PI3K/AKT	pathways.	This	study	demonstrates	the	power	of	signalome	screening	for	identifying	candidates	for	drug	repurposing.	
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associated	periodic	syndrome,	fluoroquinolone,	anti-inflammatory	
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1.	Introduction	There	is	great	potential	in	the	application	of		‘reverse-phase’	protein	microarray	(RPPA)	technology	for	multiplexed	analysis	of	signalling	pathways	and	their	chemical	modulation	[1,	2].		We	developed	a	multiplexed	RPPA	for	detecting	and	quantifying	large	numbers	of	intracellular	signalling	molecules	(a	‘signalome’)	in	lysates	from	≤20,000	cells.	Each	signalling	protein	is	detected	and	quantified	using	highly	specific,	verified,	commercially	available	antibodies	and	a	sensitive	reporter	system	[3].	Autoinflammatory	syndromes	are	orphan	diseases	with	limited	treatment	options	[4-7].	One	such	disease	is	TNF	Receptor	Associated	Periodic	Syndrome	(TRAPS)	caused	by	mutations	in	TNF	receptor-1	(TNFR1)	[8],	resulting	in	spontaneous	episodes	of	systemic	inflammation	causing	morbidity	and	potential	mortality	[9-11].		Current	treatment	options	for	TRAPS	include	corticosteroids	(with	potentially	major	side-effects)	and	cytokine-blocking	biologics;	although	the	latter	represent	a	major	advance	in	the	management	of	TRAPS,	they	are	expensive,	may	require	specialist	administration,	and	show	variable,	unpredictable,	limited	efficacy	[12,	13].		Moreover,	these	anti-cytokine	biologics	target	terminal	mediators	of	inflammation,	not	central	cellular	processes	that	drive	disease,	which	involve	intracellular	aggregation	of	misfolded	mutant	TNFR1	resulting	in	ligand-independent,	constitutive	activation	of	pro-inflammatory	signalling	pathways	[3,	14-26].	There	would	be	advantages	to	patients	and	clinicians	in	developing	drugs	for	TRAPS	(and	other	autoinflammatory	diseases)	that	are	relatively	cheap,	taken	orally,	have	a	proven	safety	record	and	minimal	side	effects	and	target	intra-cellular	pro-inflammatory	signalling	pathways	[27].	Identifying	such	drugs	through	a	repurposing	approach	would	offer	major	advantages	in	development	costs	and	safety	assessment	[28-30].		 We	used	our	RPPA	signalome	screening	method	to	investigate	changes	in	pro-inflammatory	and	apoptotic	signalling	pathways	caused	by	a	TRAPS-associated	C33Y-mutant	TNFR1.	Expression	of	the	C33Y-TNFR1	in	both	transfected	cells	and	TRAPS	patients’	peripheral	blood	mononuclear	cells	(PBMCs)	caused	subtle,	constitutive	upregulation	of	a	wide	spectrum	of	signalling	intermediates	and	their	phosphorylated	forms	associated	with	multiple	signalling	pathways,	indicating	a	pro-inflammatory/anti-apoptotic	phenotype	[3].		We	applied	this	RPPA	for	drug	repurposing	for	TRAPS	by	screening	libraries	of	existing,	approved,	off-patent,	pharmacologically	active	compounds	using	a	network	pharmacology	approach.	Over	1300	
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approved	drugs	were	screened	for	effects	on	40	signalling	molecules	associated	with	signalling	pathways	that	we	had	identified	as	being	altered	in	TRAPS.	
	
2.	Materials	and	methods	
2.1.	Cell	culture	and	treatment		The	human	liver	adenocarcinoma	SK-Hep-1	endothelial-like	cell	line	(which	expresses	low	levels	of	TNFR1)	was	stably	transfected	with	WT	or	C33Y	mutant	TNFRSF1A	gene	constructs	[18].	Cells	were	grown	in	96-well	plates	at	a	density	of	~1.5	x	104	cells	per	well	in	Dulbecco’s	modified	Eagle’s	medium	supplemented	with	10%	fetal	calf	serum,	100	units/ml	penicillin,	10	mg/ml	streptomycin,	and	5	µg/ml	blasticidin	(Invitrogen	Life	Technologies,	USA)	in	a	37°C	incubator	with	5%	CO2.		The	NINDS	and	Sequoia	compound	libraries	(1360	compounds	in	total)	were	kindly	supplied	by	MRC	Technology.		These	compounds	were	dissolved	in	DMSO,	added	to	the	cultures	at	4	ten-fold	concentrations	(10nM	to	10µM),	and	incubated	for	2	hours.		(The	final	concentration	of	DMSO	in	the	cultures	was	1%;	control	cultures	were	treated	with	1%	DMSO	alone.)			
	
2.2.	Cell	lysis	The	production	of	cell	lysates	and	RPPA	were	performed	for	the	detection	of	intra-cellular	signaling	molecules	essentially	as	described	previously	[3]:	the	cell	culture	and	RPPA	procedures	were	optimized	and	validated	at	the	scale	required	for	screening	hundreds	of	compounds.	Using	a	liquid	handling	robot	(BioTeck,	USA),	the	cells	were	washed	with	ice-cold	phosphate	buffered	saline	(PBS),	and	lysed	in	50μl	of	RIPA	lysis	buffer	(Pierce,	Thermo	Fisher	Scientific)	and	4xSDS	(0.25	M	Tris	HCl	pH	6.8,	30%	Glycerol,	8%	SDS	and	10%	2-mercaptoethanol)	at	a	ratio	of	3:1,	in	addition	to	protease	and	phosphatase	inhibitors	(Pierce,	Thermo	Fisher	Scientific)	and	5	units/ml	of	Benzonase®	Nuclease,	ultrapure	(Sigma	Aldrich,	UK).	Plates	were	incubated	on	ice	for	20	minutes	with	shaking.	Finally,	plates	were	centrifuged	at	500g	for	5	minutes	before	10µl	of	the	supernatants	were	transferred	into	a	394	well	plate	using	a	liquid	handling	robot.		
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2.3.	Reverse-phase	protein	microarray	(RPPA)		Samples	were	spotted	in	duplicate	onto	nitrocellulose-coated	glass	slides	(Grace	Bio-labs)	with	a	micro-arraying	robot	(MicroGrid	610,	Digilab,	Marlborough,	MA,	USA)	at	a	density	of	4608	features	(2304	lysates)	per	slide.	Incubation	of	the	slides	took	place	overnight	in	blocking	solution	(0.2%	I-block	(Tropix,	Bedford,	MA,	USA),	0.1%	Tween-20	in	PBS)	at	4°C	with	constant	rocking.	After	three	washes	of	5	minutes	each,	the	slides	were	incubated	with	primary	antibodies	overnight	at	4°C	with	shaking.		Forty	signaling	molecules	were	detected	using	specific	rabbit	primary	antibodies	from	Cell	Signaling	Technology	(Table	1);	these	molecules	are	associated	with	the	NF-kB,	PI3K/AKT,	MAPK	and	Jak/Stat	signaling	pathways.	In	addition,	mouse	anti-b-actin	antibody	(Sigma	Aldrich,	UK)	was	included	as	a	control	for	protein	loading.	After	washing,	slides	were	incubated	with	infrared	Licor	secondary	antibodies	(680	CW	anti-mouse	Ig	antibody	for	detection	of	b-actin	and	800	CW	anti-rabbit	Ig	antibody	for	detection	of	rabbit	antibodies),	diluted	1:5000	in	wash	buffer,	for	30	minutes	at	room	temperature	in	the	dark	with	shaking.	Slides	were	washed,	then	dried	by	centrifugation	at	500g	for	5	minutes	and	scanned	with	a	Licor	Odyssey	scanner	(LI-COR,	Biosciences)	at	21μm	resolution	at	700	nm	(red)	and	800	nm	(green).	The	resultant	TIFF	images	were	processed	with	Genepix	Pro-6	Microarray	Image	Analysis	software	(Molecular	Devices	Inc.)	to	obtain	fluorescence	data	for	each	feature	and	generate	standardized	Genepix	results	(GPR)	files.	Protein	signals	were	determined	with	background	subtraction	and	normalization	to	the	internal	house-keeping	targets	using	RPPanalyzer,	a	module	within	the	R	statistical	language	[31].		
	
2.4.	Preparation	and	culture	of	PBMCs	from	TRAPS	patient	and	control	blood	samples	Blood	samples	were	obtained	following	ethical	approval	and	informed	consent	from	five	patients	with	the	C33Y	TNFR1	mutation	and	four	healthy	age	and	sex-matched	controls.		The	study	was	approved	by	the	Nottingham	(UK)	NHS	Local	Research	Ethics	Committee	and	by	the	University	of	Nottingham	Medical	School	Research	Ethics	Committee.	The	experiments	conformed	to	the	principles	set	out	in	the	WMA	Declaration	of	Helsinki	and	the	NIH	Belmont	report.	All	the	patients	were	free	from	overt	symptoms	of	inflammation	at	the	time	that	blood	was	taken.	The	mean	age	of	the	patients	was	49	years	(range	30-71)	with	a	male:female	ratio	2:3.		Three	patients	were	being	treated	with	anakinra	and	two	with	steroids.	The	four	healthy	age	and	
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sex-matched	controls	were	of	mean	age	44	years,	range	29-63;	male:female	ratio	2:2.	20	ml	blood	was	taken	into	a	Falcon	polypropylene	tube	(Becton	Dickinson,	NJ,	USA)	containing	sterile	citrate	phosphate	dextrose	(ACD;	Baxter	Health	Care,	UK).	Blood	was	then	mixed	1:1	with	PBS	and	5	ml	Histopaque	was	underlayered	in	50ml	tubes	followed	by	centrifugation	at	900g	for	20	minutes.	The	PBMCs	were	removed,	washed	twice	in	Hank’s	Buffered	Saline	(total	volume	25	ml).		PBMCs	were	added	to	96	well	plates	at	~15,000	cells/well	in	200µl/well	of	RPMI	medium	and	cultured	with	selected	drugs	(or	1%	DMSO	alone)	for	2	hours.		The	cells	were	then	lysed	and	used	in	RPPA	for	detection	of	signalling	molecules	as	described	for	the	SK-Hep-1	cells.	
	
2.5.	Data	analysis	methodology			We	developed	a	novel	data	analysis	methodology	utilizing	mixed-effect	models	to	identify	significant	effects	of	drugs	on	the	signaling	molecules	investigated.		The	methodology	followed	two	steps;	the	details	are	given	in	the	online	Supplementary	Information.	The	first	step	compared	the	difference	between	the	signalling	pathways	in	WT	TNFR1-transfected	SK-Hep-1	cells	and	C33Y	TNFR1-transfected	SK-Hep-1	cells	to	identify	the	most	interesting	drugs.	The	aim	was	to	find	the	drugs	of	interest	that	changed	the	signaling	profile	of	the	drug-treated	C33Y-transfected	cells	to	match	that	of	the	WT-transfected	cells	without	drug	treatment.		The	second	step	was	to	perform	a	more	detailed	analysis	with	the	selected	drugs	of	interest	for	effects	on	signaling	molecule	expression	in	PBMCs	from	TRAPS	patients	with	C33Y-TNFR1	compared	to	PBMCs	from	normal	healthy	controls.	The	aim	was	to	identify	any	signaling	molecule	where	the	drug	had	a	significant	interaction	between	the	presence	of	the	C33Y	mutation	and	concentration	of	the	drug	on	the	signalling	molecule’s	level	of	expression	using	mixed-effect	models.		We	further	investigated	each	significant	interaction	that	was	identified	to	distinguish	those	that	significantly	normalized	(i.e.	reduced)	the	expression	of	the	signaling	molecule	in	C33Y	PBMCs	towards	that	seen	in	WT	PBMCs	with	increasing	concentration	of	the	drug,	and	those	that	exaggerated	the	difference	in	signaling	molecule	expression	between	C33Y	and	WT	PBMCs	with	increasing	drug	concentration.				 For	the	analysis,	we	used	the	open	source	statistical	analysis	language	R.		The	package	lme4	was	used	to	implement	the	mixed	effects	model	and	the	Base	statistical	package	was	used	to	perform	the	likelihood-ratio	test.		The	plots	were	produced	using	the	ggplot2	package.	
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3.	Results	
3.1.	Establishing,	optimising	and	validating	the	assay	methodology		The	cell	culture	and	RPPA	procedures	were	rigorously	optimised	at	the	scale	required	for	screening	hundreds	of	drugs.		After	optimization	of	robot	performance,	MTT	and	BCA	assays	were	performed,	using	standard	procedures,	to	determine	SK-Hep-1	cell	viability	and	protein	recovery	on	robotically	seeded	wells,	performed	on	separate	days,	to	determine	CVs	for	growth	uniformity.	The	BCA	assay	intra-plate	CV	was	6.63±3.2%	and	intra-plate	CV	based	upon	MTT	assays	averaged	7.17	±1.00%	(Figure	1A).	Constitutively	expressed	proteins,	including	!-actin,	α-tubulin,	Nup98,	GAPDH	and	!-catenin	were	assayed	by	reverse-phase	protein	microarray	from	replicated	96	well	culture	plates,	each	well	containing	105	cells,	to	determine	the	uniformity	of	signal	detection.		Three	96	well	plates	produced	on	separate	days	were	analysed,	with	each	well	printed	as	duplicate	features	on	the	arrays.		Analysis	revealed	that	!-actin	and	!-catenin	showed	acceptable	inter-plate	CVs	(18.52%	for	!-actin,	21.7%	for	!-catenin,	whereas	GAPDH,	Nup98	and	α-tubulin	gave	higher	CVs	across	all	assay	plates	tested	(31.8,	31.0	&	23.9%	respectively;	see	Figure	1B).	!-actin	was	therefore	the	choice	for	use	as	a	normalizer,	due	also	to	the	higher	signal	levels	routinely	detected	in	comparison	to	optimized	anti-!-catenin	antibody	batches	(approximately	3.5-fold	higher),	under	standardized	probing	and	scanning	conditions.		Quality	control	of	RPPA	printing	and	processing	was	further	assessed	to	determine	print	reproducibility	and	inter	and	intra-array	variation.	Individual	samples	were	routinely	printed	across	multiple	arrays,	and	as	replicates	upon	an	array;	this	provided	an	ideal	situation	to	monitor	uniformity.	Using	the	optimized	workflow,	arrays	were	generated	and	probed	for	b-actin.	Each	array	contained	over	760	individual	features.	Average	inter-array	actin	CVs	for	individual	samples,	printed	in	duplicate	in	each	array	and	processed	as	independent	arrays,	was	10.66±0.96%	(array	n=11	for	CV	calculation,	from	the	mean	of	duplicate	features	per	sample,	unique	sample	n	for	CV	averaging	=	384).	Mean	intra-array	actin	CV,	calculated	from	CVs	of	treatment	replicates	=	10.66±0.45%	(n	=	14	sample	groups,	consisting	of	between	32	and	64	replicates	per	group)	(figure	1C).		
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3.2.	Stimulation	with	PMA	to	examine	the	system	capabilities	for	measuring	signal	transduction		 Verification	of	PMA’s	ability	to	stimulate	SK-Hep-1	cells	was	initially	assessed	by	measurement	of	HSP27	phosphorylation	and	thrombospondin	expression	in	the	presence	of	PMA,	after	initial	testing	of	a	range	of	PMA	concentrations	(data	not	shown).	One	hundred	nM	PMA	was	chosen	as	an	optimal	stimulus,	and	a	1hr	exposure	to	PMA	(figure	1D(i)),	although	PMA	exposures	up	to	24hrs	were	performed	(data	not	shown).		The	strictly	standardized	mean	difference	parameter	(SSMD)	[32,	33]	β	score	for	pHSP27	after	1hr	exposure	to	100nM	PMA	was		6.68,	with	β	>5	categorized	as	an	‘extremely	strong’	effect	on	the	SSMD	scale.		The	corresponding	Z’	was	0.368.		Similarly,	responses	observed	in	the	phosphorylation	state	of	ERK1/2	(pERK1/2)	response	to	the	inhibitor	PD98059	also	give	insignificant	Z’	values	(Z’=0.336)	despite	clear	visible	evidence	of	effect	(figure	1Dii),	also	indicated	by	an	extremely	strong	SSMD	β=6.16.	SSMD	was	therefore	further	examined	as	an	alternative	and	possibly	more	robust	method	for	QC	of	the	initial	assay,	as	it	is	designed	to	deal	with	moderate	positive	to	negative	effect	differentials	(e.g.	RNAi	experiments),	and	therefore	has	utility	when	observing	intracellular	signalling	effects,	where	the	range	of	response	may	be	1.5-4	fold	maximal	difference.	(SSMD	absolute	β	scores	of	above	2	indicate	strong	thresholds	for	hit	determination	and	assay	QC	for	activation	and	inhibition	assays	where	moderate	effects	are	seen.)		 Figure	1E(i-iii)	demonstrates	the	use	of	the	optimized	screening	methodology	when	examining	14	intracellular	signaling	intermediates,	and	the	utility	of	the	SSMD	score	to	identify	potential	changes	due	to	compound	effects.	As	expected,	PD98059	caused	down-regulation	of	pERK1/2	and	FR180204	had	no	effect	on	any	signaling	intermediates.		SB203580	also	down-regulated	pERK1/2	expression.	
3.3	Screening	of	the	BioMol	kinase	inhibitor	set	The	validation	of	the	methodology	for	screening	large	numbers	of	compounds	that	affect	signaling	pathways	was	successfully	performed	by	using	the	system	to	screen	the	80	compound	BioMol	kinase	inhibitor	(KI)	library	(kindly	provided	by	MRC	Technology).		Untransfected,	WT-TNFR1	and	C33Y-TNFR1	transfected	SK-Hep-1	cell	lines	were	exposed	to	these	KIs.	The	BioMol	set	contains	a	broad	range	of	KIs,	some	of	which	inhibit	kinases	associated	with	the	TRAPS	disease	profile.		In	some	cases,	inhibitors	within	the	set	show	known,	broader	KI	effects.	This	
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library	therefore	provided	a	well-defined	compound	group	for	testing	the	system	out,	with	full	expectation	of	both	on	and	off-target	positive	hits.	The	resultant	data	set	was	analysed	and	correlated	to	both	the	known	activities	and	effective	concentrations	of	each	kinase	inhibitor	and	any	detected	‘promiscuous’	activity	or	global	toxicity.	This	represented	a	key	test	of	the	system’s	potential	for	larger	scale	application.		The	80	compounds	of	the	BioMol	inhibitor	set,	and	DMSO	control	wells,	were	used	at	3	concentrations,	determined	by	literature	analysis	to	give	a	suitable	range	of	dilutions,	namely	1,	10	and	50μM	final	concentrations.	All	dilutions	were	generated	in	100%	DMSO	stock	to	preserve	solubility,	and	final	DMSO	concentrations	in	the	SK-Hep-1	cell	cultures	was	1%,	which	is	well	tolerated	by	the	cells,	as	determined	by	prior	assays.	Three	independent	replicate	screens	were	performed,	and	all	wells	within	the	screen	(each	representing	~15000	cells	per	seeding)	were	spotted	onto	nitrocellulose	arrays	as	technical	duplicates,	providing	~3900	features	per	array.	Forty	arrays	were	probed	with	antibodies	against	the	target	molecules	shown	in	Table	1.Each	array	was	concurrently	probed	with	anti-b-actin	to	allow	normalization	for	cell	density	differences	(figure	2).	A	robust	version	of	the	SSMD	approach	[32,	33]	was	applied	to	the	resultant	fluorescence	data,	after	filtering	spot	features	to	remove	poor	spots	(determined	by	examining	spot	morphology	data	within	the	results	files	(circularity,	feature	size	and	mean	pixel	intensity	comparison	to	median	pixel	intensity	to	detect	uneven	feature	intensity,	%	of	pixels	in	feature	>	mean	local	background	intensity	+2SD	of	background	pixel	intensity).	Table	2	summarizes	the	key	SSMD	scores	obtained	from	all	the	replicate	experiments	for	those	compounds	which	consistently	gave	SSMD*	of	>2	or	<-2	across	all	three	replicates.	This	is	a	robust	measure	of	the	hits	as	it	is	based	upon	whether	all	3	replicates	at	any	given	treatment	concentration	show	similar	SSMDs.		The	data	from	this	screen	indicates	that	the	hit	rate	was	approximately	as	predicted	for	the	BioMol	set,	being	5.5%	of	compounds	yielding	hits	(within	the	SSMD	criteria	stated	in	Table	2)	with	the	SK-Hep-1	cells	transfected	with	TNFR1-C33Y,	and	4.2%	for	the	TNFR1-WT	SK-Hep-1	transfectant.	Differential	responses	from	the	SK-Hep-1	cells	expressing	the	TNFR1	C33Y	mutation	were	seen,	relative	to	cells	expressing	the	WT	receptor.	For	example,	H-8	(nominally	described	as	a	ROCK2	inhibitor)	is	an	isoquinaline	sulphonamide	derivative	and	one	of	the	earliest	kinase	inhibitors	described.	It	has	multiple	effects	upon	the	SK-Hep-1	C33Y	cell	type,	giving	strong	to	extremely	strong	SSMD	scores	from	32	of	40	targets	examined	when	
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applied	at	50μM,	15	of	40	targets	at	10	and	1μM.	It	is	reported	in	the	literature	to	lack	specificity	[34],	and	our	screen	indicates	directly	or	indirectly	that	it	affects,	amongst	other	molecules,	phosphorylation	of	GSK-3B,	with	SSMDs	of	-2.47,	-2.88	-3.86	at	1,	10	and	50μM	respectively;	AKT	phosphorylation	(both	serine	and	threonine	sites);	HSP27	phosphorylation;	phosphorylation	of	MAPKAPK-2	(Thr334)	and	phosphorylation	of	MKK3	(Ser189)/MKK6	(Ser207).However,	in	the	SK-Hep-1	WT	transfectants,	H-8	only	shows	SSMD*	scores	over	2	or	below	-2	for	6	target	molecules,	and	only	at	the	highest	concentration	of	H-8	(50μM),	including	phospho-c-Jun	(S63),	phospho-Ask1(S83),	PTEN,	cRAF,	Tak1	and	Ask1.	All	are	represented	in	the	H-8	affected	targets	from	the	SK-Hep-1	C33Y	transfected	cells	except	for	Tak1	and	c-Raf,	which	are	slightly	below	the	thresholds	stated.		Examples	of	more	specific	effects,	though	not	entirely	specific	at	the	highest	inhibitor	concentrations,	include:i)	the	anti-tumor	agent	Damnacathal,	giving	robust	SSMD	scores	over	threshold	(taken	as	SSMD*	>2	or	<-2)	for	phospho-PI3K	at	10	and	50μM	and’	at	50μM,	affecting	phospho-	ELK1,	phospho-ERK1/2	and	phospho-NFkB	P65;ii)	AG-494	is	a	member	of	the	tyrphostin	family	of	tyrosine	kinase	inhibitors	and	is	a	potent	inhibitor	of	EGF	receptor	autophosphorylation	and	off-target	effects	are	known.	In	our	screen	we	saw	effects	of	Ag-494	on	phosphorylation	of	ELK1	(SSMD*	of	2.66,	2.67	&	3.38	at	1,	10	and	50μM	respectively)	and	ATF-2,	with	lesser	effects	on	phospho-BAD	and	phospho-PI3K,	but	only	in	the	SK-Hep-1	WT	cells,	not	with	the	C33Y	transfectant.			We	also	saw	compounds	that	elicit	little,	if	any	response,	however	the	targets	for	many	inhibitors	within	the	BioMol	set	are	outside	the	pathways	linked	to	the	targets	we	are	examining,	so	this	is	not	surprising.	Off	target	effects	are,	however,	still	apparent,	with	H-8	being	a	prime	example.		
3.4.	Identification	of	lead	compounds	from	the	drug	repurposing	library	screening		The	screening	of	1360	drugs	in	the	NINDS	and	Sequoia	compound	libraries	at	4	concentrations	for	effects	on	40	signalling	molecules	in	the	2	SK-Hep-1	cell-lines	(transfected	with	WT	or	C33Y	TNFR1),	with	duplicate	lysate	prints	on	the	RPPA	slides,	generated	870,400	data	points.		An	analysis	method	was	developed	to	rank	all	the	drugs	at	each	concentration	in	terms	of	how	closely	the	signalome	of	the	C33Y-TNFR1	transfectants	treated	with	the	drug	matched	the	signalome	of	the	WT-TNFR1	transfectants	without	the	drug	(see	the	online	Appendix	A	–		Supplementary	Information).		Thus,	the	highest-ranking	drugs	gave	the	best	
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alignment	of	the	C33Y	signalome	with	the	untreated	WT	signalome.		This	generated	>5400	ranks	with	lower	scores	corresponding	to	higher	ranks.		The	range	of	scores	was	11	(ranked	1)	to	>3.8	x	106.		Figure	3a	shows	the	cumulative	profile	of	scores	(expressed	as	binned	log10	values)	for	all	drugs	at	all	concentrations;	this	shows	a	reasonably	Gaussian	distribution	with	geometric	mean	score	102	(2.01	log	units)	and	standard	deviation	0.26	log	units.	The	drug/concentration	combinations	ranked	1-35,	with	scores	11-31	(Table	3)	were	examined	to	select	a	small	number	for	further	investigation	(see	the	Discussion	for	a	broader	consideration	of	the	top-ranked	drugs).		The	selection	criteria	were	that	drugs	should	have	proven	safety	profiles	in	humans,	they	should	represent	a	range	of	drug	classes	in	terms	of	established	therapeutic	uses,	and	that	there	should	be	literature-based	evidence	of	them	showing	anti-inflammatory	effects.		The	drugs	were	also	ranked	on	the	median	score	of	all	four	of	the	drug	concentrations	tested.		On	this	basis,	the	drugs	selected	(with	highest/median	score)	were:	cefamandole	nafate	(14/38)	–	a	cephalosporin	antibiotic;	lomefloxacin	hydrochloride	(19/55)	–	a	fluoroquinolone	antibiotic;	estradiol-3-sulfate	(19/122)	–	a	female	steroid	hormone;	ketoprofen	(22/48)	–	a	non-steroidal	anti-inflammatory	drug;	fosfomycin	(22/65)	–	a	phosphonic	acid	antibiotic.		In	addition,	methylprednisolone	(30/54)	was	chosen	as	a	positive	control	because	its	primary	use	is	as	an	anti-inflammatory/immunosuppressive	drug;	fluoxetine	(471/598)	–	a	selective	serotonin	reuptake	inhibitor	with	no	known	anti-inflammatory	effects	–	was	chosen	as	a	negative	control.			Further	validation	of	this	choice	of	compounds	is	provided	by	the	presentation	of	data	in	figure	3b,	which	shows	all	the	compounds	tested,	but	clustered	into	structural	families	and	positioned	according	to	the	mean	score	logged	to	base	10	of	each	cluster	and	the	number	of	compounds	in	the	cluster.		This	highlights	the	fluoroquinolones	(and	closely	related	quinolones),	the	estradiols	and	cephalosporins,	together	with	the	‘positive	control’	glucocorticoids.		Berberines	were	also	highlighted	in	this	analysis	of	the	data	(figure	3b),	but	the	highest	ranking	of	these,	ethaverine,	was	ranked	only	114th	(100nm,	score	43).			In	addition,	a	Bayesian	model	was	developed	from	the	tested	compounds	and	their	scores	to	classify	and	predict	active	and	inactive	compounds	based	on	structural	features.		This	model	was	applied	to	all	untested	compounds	listed	in	ChEMBL	as	being	in	phase	IV	clinical	trials	with	molecular	weights	between	100	and	600.		Figure	3c	shows	that	this,	again,	highlighted	quinolones,	cephalosporins,	estradiols	and	glucocorticoids	(and	other	steroids)	as	the	main	compounds	predicted	to	be	active	in	our	
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signalome	assay,	thereby	further	supporting	our	choice	of	compounds	for	further	testing.	(Compounds	shown	as	inverted	triangles	fail	‘Lipinski’s	rule	of	five’	and	are	unlikely	to	function	as	orally	active	drugs	in	humans	[35].)		
3.5.	Further	screening	of	lead	compounds	on	peripheral	blood	mononuclear	cells	from	TRAPS	
patients	and	healthy	controls		The	seven	selected	drugs	indicated	above	were	screened	at	4	ten-fold	concentrations	on	unstimulated,	cultured	PBMCs	from	5	C33Y-TNFR1	TRAPS	patients	and	4	normal	healthy	controls.		Expression	of	the	same	40	signalling	molecules	detected	in	the	SK-Hep-1	transfectants	was	analysed	by	protein	microarray	in	lysates	made	from	the	PBMCs	after	2	hours	of	treatment	with	the	drugs.		The	resulting	data	was	analysed	using	mixed-effect	models	to	identify	drugs	that	induced	a	significant	dose-dependent	reduction	of	signalling	molecules	in	the	TRAPS	patients’	PBMCs	towards	the	level	seen	in	control	PBMCs,	or	caused	a	dose-dependent	increase	in	signalling	molecule	expression	in	TRAPS	patients’	PBMCs	relative	to	levels	in	control	PBMCs	(for	mathematical	details,	see	the	online	Supplementary	Information).		A	significance	level	of	10%	(p	≤	0.1)	was	employed	due	to	the	relatively	small	sample	size.		The	results	for	signalling	molecules	whose	expression	in	TRAPS	patients’	PBMCs	were	significantly,	dose-dependently,	decreased	towards	normal	levels,	or	increased	away	from	normal	levels,	by	particular	drugs	are	summarised	in	table	4.		Cefamandole	nafate	and	ketoprofen	each	reduced	expression	of	only	a	single	signalling	molecule	in	TRAPS	patients’	PBMCs	(PI3K.P110	and	SOCS3,	respectively,	with	the	latter	being	an	inhibitor	of	cytokine	signalling),	and	both	of	these	drugs	upregulated	expression	of	numerous	signalling	molecules	(12	and	7,	respectively).		Only	upregulation	of	signalling	molecules	in	TRAPS	patient’s	PBMCs	was	observed	with	estradiol-3-sulphate,	fosfomycin,	and	even	with	methylprednisolone;	no	significant	effects	were	observed	with	fluoxetine.		By	contrast,	lomefloxacin	showed	significant	dose-dependent	reduction	of	seven	signalling	molecules	in	TRAPS	patients’	PBMCs	across	all	four	different	pro-inflammatory	signalling	pathways,	and	upregulation	of	four	signalling	molecules	(table	4).		Thus,	this	identified	lomefloxacin	as	a	lead	compound	in	terms	of	down-regulating	the	pro-inflammatory	signalome	of	TRAPS	patients’	PBMCs.		 Lomefloxacin	is	a	member	of	the	fluoroquinolone/quinolone	class	of	antibiotics	that	act	as	
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bacterial	DNA	gyrase	inhibitors.		Indeed,	it	is	of	note	that	the	highest-ranking	compound	in	the	initial	screen	of	1340	drugs	was	the	quinolone	antibiotic	piromidic	acid	(score	11)	and	that	the	fluoroquinolone	ofloxacin	was	ranked	twentieth	(lomefloxacin	was	ranked	ninth).		Furthermore,	piromidic	acid,	lomefloxacin	and	ofloxacin	were	amongst	only	31	out	of	the	1360	drugs	for	whom	all	four	drug	concentrations	gave	scores	≤100	(three	of	the	others	were	the	recognised	anti-inflammatory	drugs	prednisolone,	methylprednisolone	and	hydrocortisone).		Also	of	relevance	is	the	empirical	observation,	made	independently	of	the	current	findings,	that	a	TRAPS	patient	with	the	C33Y-TNFR1	mutation,	who	was	given	the	fluoroquinolone	moxifloxacin	to	treat	a	pneumococcal	chest	infection	also	showed	dramatic	improvements	in	her	TRAPS	symptoms,	and	this	was	maintained	for	two	years	whilst	moxifloxacin	administration	continued	[36].		However,	it	is	possible	that	this	therapeutic	effect	was	due	to	the	drug’s	antimicrobial	activity;	furthermore,	administration	of	fluoroquinolones	to	three	other	C33Y-TNFR1	TRAPS	patients	showed	no	benefit	[36].			Moxifloxacin	was	the	third	highest	ranked	fluoroquinolone	in	the	library	screen	(score	50)	after	lomefloxacin	and	ofloxacin.		This	adds	further	weight	to	the	potential	anti-inflammatory	effects	of	fluoroquinolones	in	TRAPS.		Moxifloxacin	was	not	screened	for	effects	on	signaling	molecules	in	TRAPS	patients’	PBMCs	in	the	present	study	as	it	fell	outside	of	the	top	35	ranked	compounds;	however,	it	remains	of	interest	to	test	moxifloxacin	in	this	assay.	
4.	Discussion	
We	previously	demonstrated	that	multiple	pro-inflammatory	signaling	pathways	are	activated	in	TRAPS	[3].		Current	therapies	include	corticosteroids	with	significant	side-effects	when	used	long-term,	and	expensive	biologics	that	neutralize	cytokines	produced	as	a	consequence	of	the	disease	mechanisms,	rather	than	targeting	the	underlying	aetiology	[12,	27].		To	address	this,	we	developed,	optimized	and	validated	a	protein	microarray-based	network	pharmacology	approach	to	identify	repurposing	drugs	that	simultaneously	target	multiple	signaling	pathways	that	are	activated	in	TRAPS.		Repurposing	of	existing	drugs	is	a	cost-effective	and	efficient	means	of	exploiting	drugs	whose	safety	and	pharmacological	profiles	are	established,	reducing	development	time	and	cost	for	new	therapeutic	indications.		Development	costs	of	repurposed	drugs	are	about	60%	that	of	novel	compounds,	and	they	are	three	times	more	likely	to	gain	market	approval	[37].	
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The	first	stage	of	the	screening	strategy	utilizing	the	SK-Hep-1	C33Y	and	WT	TNFR1	transfectants	as	the	target	cells	highlighted	several	compounds	of	interest	within	the	top	ranks	(Table	3).		Three	quinolone/fluoroquinolone	antibiotics	are	represented	in	the	top	35	compounds:	piromidic	acid	(ranked	1	and	22),	lomefloxacin	(ranked	8)	and	ofloxacin	(ranked	19).		Piromidic	acid	is	a	first-generation	quinolone	antibiotic	that	is	no	longer	widely	used,	which	is	why	it	was	not	chosen	for	further	analysis	in	this	study;	lomefloxacin	and	ofloxacin	are	second	generation	fluoroquinolone	antibiotics.		Significant	evidence	of	in	vivo	and	in	vitro	anti-inflammatory	activities	of	fluoroquinolones	has	been	reported	previously	[38-42].		In	particular,	with	regard	to	the	effects	of	fluoroquinolones	on	pro-inflammatory	signaling	intermediates,	it	has	been	reported	that	norfloxacin	and	gemifloxacin	reduce	NFkB	expression	and	activation	[43-45],	and	that	garenoxacin	inhibits	Erk1/2	phosphorylation	[46].		Moxifloxacin	also	inhibits	Erk1/2,	JNK	and	NFkB	[47-49].		Certain	derivatives	of	fluoroquinolones	have	been	reported	selectively	to	inhibit	PI3Kg	[50].		Four	other	antibiotics	occur	in	the	top	35	compounds:	these	are	the	cephalosporins	cefamandole	nafate	(ranked	2	and	13)	and	cefuroxime	sodium	(ranked	3);	metampicillin	sodium	(ranked	9)	and	fosfomycin	(ranked	12).		There	is	some	evidence	for	immune-modulatory	properties	of	cephalosporins	[51].		Fosfomycin	has	been	reported	to	modulate	cytokine	production	by	inhibiting	NFkB	activation	[52].		Four	cyclo-oxygenase	(COX)	inhibitors	are	represented	in	the	top	35	compounds:	carprofen	(ranked	4	and	28),	ketoprofen	(ranked	14),	tolfenamic	acid	(ranked	20)	and	mefenamic	acid	(ranked	23).		Carprofen	is	designated	for	veterinary	use	only.		With	respect	to	ketoprofen,	although	it	was	observed	only	to	down-regulate	the	inhibitor	of	cytokine	signalling	SOCS3	in	the	current	study,	others	have	reported	that	it	suppresses	production	of	IL-1b	and	TNFa in	LPS-stimulated	human	dental	pulp	cells,	and	to	inhibit	phosphorylation	of	ERK	and	JNK	[53].	 Methylprednisolone,	a	widely	used	anti-inflammatory	and	immunosuppressive	corticosteroid	drug,	is	ranked	32.		Hecogenin	(ranked	29)	is	a	steroidal	saponin	derived	from	plants	(genus	Agave	–	‘sisal’)	used	pharmaceutically	as	a	precursor	for	steroid	hormone	synthesis;	it	is	reported	to	inhibit	the	synthesis	of	pro-inflammatory	cytokines	like	IL-1b	[54].		Particularly	interesting	is	the	occurrence	of	several	oestrogens	amongst	the	top	35	compounds:	estriol	benzyl	ether	(ranked	6	and	10),	estrdiol-3-sulphate	(ranked	7)	and	estradiol	acetate	(ranked	15).		It	is	well	recognised	that	certain	autoimmune	diseases	(e.g.	multiple	sclerosis	and	
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rheumatoid	arthritis)	ameliorate	during	pregnancy	in	female	patients,	when	levels	of	estriol	increase.		A	recently	published	study	provides	some	evidence	that	female	patients	with	relapsing/remitting	multiple	sclerosis	who	were	treated	with	estriol	in	combination	with	glatiramer	acetate	experienced	fewer	relapses	of	disease	than	patients	receiving	glatiramer	acetate	alone	[55].	Three	vitamins	are	represented	in	the	top	35	compounds,	namely:	retinol/vitamin	A	(ranked	17);	lapachol	(ranked	34),	which	is	a	derivative	of	vitamin	K;	and	ergocalciferol/vitamin	D2	(ranked	35).		There	is	good	evidence	for	immunomodulatory	activity	of	vitamin	D,	and	association	between	poor	vitamin	D	status	and	increased	risk	of	various	autoimmune	diseases	[56];	evidence	also	indicates	that	vitamin	D	may	reduce	the	risk	of	severe	exacerbations	of	asthma	[57].			Amlexanox	(ranked	30)	is	an	anti-inflammatory	agent	used	for	the	treatment	of	aphthous	ulcers	and	(in	Japan)	it	is	used	to	treat	bronchial	asthma,	allergic	rhinitis	and	conjunctivitis.		It	has	been	shown	to	inhibit	the	IkB	kinases	TBK1	and	IKKe	and	therefore	reduces	NFkB	activation	[58-61].		There	are	also	reports	of	amlexanox	inhibiting	G	protein-coupled	receptor	kinase	5	[62,	63]	and	that	it	binds	to	the	S100	proteins	A4	and	A13	[64,	65].		This	may	also	help	to	explain	the	anti-inflammatory	effects	of	amlexanox	as	S100A4	is	reportedly	a	TLR4	agonist	[66].	Fenspiride	hydrochloride	(ranked	25)	is	a	bronchodilator	with	anti-inflammatory	properties	that	may	act	as	an	antagonist	to a-adrenergic	and	H1	histamine	receptors.		Pindolol	(ranked	18)	and	ephedrine	hydrochloride	(ranked	26)	are	b-adrenoceptor	ligands:	they	are	an	antagonist	and	agonist,	respectively,	but	with	some	structural	similarities.	The	second	stage	screening	of	selected	compounds	on	PBMCs	from	TRAPS	patients	and	healthy	controls	highlighted	the	anti-inflammatory	effects	of	the	fluoroquinolone	antibiotic	lomefloxacin,	as	this	down-regulated	signaling	molecules	associated	with	four	pro-inflammatory	signaling	pathways	that	are	activated	in	TRAPS.		Independent	of	this,	the	report	that	a	TRAPS	patient	showed	significant	therapeutic	anti-inflammatory	benefit	from	treatment	with	the	fluoroquinolone	moxifloxacin	[36]	adds	significant	further	support	to	the	potential	of	fluoroquinolones	as	anti-inflammatory	agents	in	the	management	of	TRAPS.		Targeting	signaling	molecules	in	inflammatory	diseases	is	exemplified	by	the	recent	approval	of	JAK	inhibitors	in	rheumatoid	arthritis	[67].			
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Figure	4	summarises	the	effects	of	lomefloxacin	that	we	observed	on	signaling	pathways	in	TRAPS	patients’	PBMCs:	the	expression	of	molecules	shown	in	red	was	dose-dependently	down-regulated	by	lomefloxacin,	those	in	green	were	upregulated,	and	those	in	blue	were	unaffected.		This	is,	necessarily,	a	simplified	representation	as	many	signalling	molecules	associate	with	more	than	one	signalling	pathway,	and	can	have	opposing	effects	in	different	contexts.	However,	figure	4	demonstrates	how	lomefloxacin	mediates	anti-inflammatory	effects	by	down-regulating	pro-inflammatory	signalling	molecules	(p38MAPK,	cSrc,	RIP,	AKT1/2,	Jak2)	and	upregulating	anti-inflammatory	molecules	(e.g.	cIAP1/2)	–	even	the	cRaf-Erk1/2	pathway	can	have	anti-inflammatory	actions	by	inhibiting	Stat3	[68].		Conversely,	the	down-regulation	of	the	PI3K	inhibitor	PTEN	may	be	a	feedback	consequence	of	the	negative	regulation	of	this	pathway	by	the	down-regulation	of	phospho-AKT1/2	by	lomefloxacin.	The	present	study	does	not	elucidate	the	molecular	mechanisms	of	the	effects	of	lomefloxacin	on	pro-inflammatory	signalling	pathways,	which	will	be	the	subject	of	further	investigations.		Certain	fluoroquinolone	derivatives	have	been	reported	to	selectively	inhibit	PI3Kg		[50];	however,	lomefloxacin	appears	to	have	broader	effects	on	a	number	of	pro-inflammatory	signalling	pathways.		The	findings	reported	here	do,	however,	provide	a	mechanistic	basis	for	the	independent,	empirical	observation	of	the	anti-inflammatory	therapeutic	benefit	of	moxifloxacin	in	a	TRAPS	patient	[36],	and	concurs	with	other	reports	of	inhibitory	effects	of	moxifloxacin	on	MAP-kinases	and	NFkB	[47-49].		However,	it	cannot	be	excluded	that	the	beneficial	effects	of	moxifloxacin	in	this	patient	were	due	to	its	anti-microbial	activity	against	infections	that	might	otherwise	have	triggered	TRAPS-associated	inflammation;	furthermore,	moxifloxacin	and	ciprofloxacin	were	not	beneficial	in	three	other	TRAPS	patients	with	the	C33Y-TNFR1	mutation	[36].	When	considering	broadening	the	therapeutic	use	of	FQs	beyond	use	as	anti-microbials,	it	is	important	to	bear	in	mind	that	these	drugs	can	have	significant	toxic	side	effects	and	their	application	is	restricted	in	certain	groups,	particularly	children	[69,	70];	also,	the	dangers	of	promoting	microbial	resistance	through	wider	use	must	be	considered	[71].		Thus,	generating	modified	derivatives,	or	finding	structurally-related	alternatives	to	FQs	that	have	reduced	toxicity	and	anti-microbial	activity	but	show	enhanced	anti-inflammatory	activity,	could	provide	a	valuable	source	of	novel	anti-inflammatory	agents.		More	generally,	the	present	study	demonstrates	the	value	cell-lysate	RPPA	for	screening	large	numbers	of	chemicals	for	effects	on	
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multiple	signaling	molecules	in	the	context	of	drug	development	and	repurposing.	
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TABLE	1.		List	of	signalling	molecules	detected	by	RPPA.		
	
	
NF-kB	Pathway	
	
	
PI3K/AKT	Pathway	
	
MAPK	Pathway	
	
JAK/STAT3	TRAF2	 c-Raf	 P38	MAPK	 STAT3	p-RIP2(S176)	 p-c-Raf	 p-P38	MAPK	(T180/Y182)	 p-STAT3	(Tyr705)	p-IkB	alpha	 GSK3-B	 p-Sek1/MKK4	(Thr261)	 p-ELK1	p-NFkBp65	 p-GSK3-B	 p-HSP27(Ser82)	 SOCS3	A20/TNFAIP3	 PTEN	 p-MAPKAPK-2(Thr334)	(27B7)	 JAK2	c-IAP1	 p-PTEN	 Ask1	 p-JAK2	(Tyr221)		 AKT	 TAK1	 p-ATF-2	(Thr71)		 p-AKT	Serine	 p-MKK3(Ser189)/MKK6(Ser207)	 c-FLIP		 p-AKT	Threonine	 ERK1/2	 		 p-BAD	136	 p-ERK1/2	 		 p-PI3k	 p-SAPK/JNK(Thr)	 		 p-PDK1	 p-c-Jun	(S63)	 		 	 p-Ask-1	(S83)	 		 	 14-3-3-epsilon	 	
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TABLE	2.		SSMD	scores	calculated	for	the	effects	of	80	kinase	inhibitors	in	the	BioMol	set	of	compounds	on	40	signalling	molecules	in	SK-Hep-1	cells	transfected	with	C33Y-TNFR1	or	WT-TNFR1.		
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TABLE	3.		Drug/concentration	combinations	ranked	1-35	(out	of	>5,000	ranks)	by	screening	for	effects	on	signalling	molecules	in	C33Y-TNFR1-transfected	SK-Hep-1	cells	compared	to	WT-TNFR1-transfected	SK-Hep-1	cells.	Compounds	selected	for	further	study	are	shown	in	bold.			
RANK	 DRUG:	CONCENTRATION	 	 	 	 								SCORE					NATURE	/	FUNCTION	 	
1______PIROMIDIC	ACID:100	 11.40							Quinolone	antibiotic	
2______CEFAMANDOLE	NAFATE:100	 13.71							Cephalosporin	antibiotic	3______CEFUROXIME	SODIUM:100	 15.52							Cephalosporin	antibiotic	4______CARPROFEN:10	 16.15							COX	inhibitor	/	NSAID	5______PRALIDOXIME	MESYLATE:100	 17.40							Antidote	for	organophosphate	poisoning	6______ESTRIOL	BENZYL	ETHER:10000	 18.21							Oestrogen	steroid	hormone	
7______ESTRADIOL-3-SULFATE:100	 18.79							Oestrogen	steroid	hormone	
8______LOMEFLOXACIN	HYDROCHLORIDE:100	 19.10							Fluoroquinolone	antibiotic		9______METAMPICILLIN	SODIUM:100	 19.65							b-lactam	antibiotic		10_____ESTRIOL	BENZYL	ETHER:100	 20.52							Oestrogen	steroid	hormone	11_____5-FLUORO-5'-DEOXYURIDINE:100	 20.62							Inhibitor	of	thymidine	synthesis	
12_____FOSFOMYCIN:100	 21.85							Phosphonic	acid	antibiotic	13_____CEFAMANDOLE	NAFATE:10000	 22.10							Cephalosporin	antibiotic	
14_____KETOPROFEN:100	 22.29							COX	inhibitor	/	NSAID	15_____ESTRADIOL	ACETATE:100	 22.30							Oestrogen	steroid	hormone	16_____METHYLERGONOVINE	MALEATE:10000	 23.22							Inducer	of	smooth	muscle	contraction	17_____RETINOL:100	 24.47							Vitamin	A	18_____PINDOLOL:100	 24.59								b-Adrenoceptor	antagonist	19_____OFLOXACIN:100	 24.92							Fluoroquinolone	antibiotic	20_____TOLFENAMIC	ACID:100	 26.31							COX	inhibitor	/	NSAID	21_____IODIPAMIDE:10000	 26.40							Radiopaque	contrast	medium	22_____PIROMIDIC	ACID:10	 26.71							Quinolone	antibiotic	23_____MEFENAMIC	ACID:100	 27.18							COX	inhibitor	/	NSAID	24_____BUTAMBEN:10000	 27.92							Anaesthetic	25_____FENSPIRIDE	HYDROCHLORIDE:100	 28.76							Antitussive	/	anti-inflammatory	26_____EPHEDRINE	(1R,2S)	HYDROCHLORIDE:100	 28.89							b-Adrenoceptor	agonist	/	bronchodilator	27_____DIETHYLTOLUAMIDE:1000	 29.13							Insect	repellant	28_____CARPROFEN:100	 29.70							COX	inhibitor	/	NSAID	29_____HECOGENIN:10000	 29.71							Steroid	saponin	30_____AMLEXANOX:100	 30.05							Anti-inflammatory/anti-allergic	agent	31_____GALANTHAMINE	HYDROBROMIDE:10000	 30.35							Alkaloid	used	in	dementia	treatment	
32_____METHYLPREDNISOLONE:100	 30.40							Anti-inflammatory	glucocorticoid	33_____AMINOLEVULINIC	ACID	HYDROCHLORIDE:100	 30.80							Porphyrin	precursor	for	photodynamic	therapy	34_____LAPACHOL:100	 30.89							Vitamin	K	derivative	35_____ERGOCALCIFEROL:10000	 30.97							Vitamin	D2	
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TABLE	4.		Summary	of	all	instances	in	which	increasing	concentrations	of	the	lead	drugs	significantly	(p	≤	0.1;	precise	p	values	given	in	brackets)	reduced	(			)	or	increased		(				)	expression	of	signalling	molecules	in	PBMCs	from	C33Y-TNFR1	TRAPS	patients	towards	levels	seen	in	PBMCs	from	normal	healthy	control	subjects.			
Drug	
	
	 NFkB	
pathway	
	
PI3K	pathway	 MAPK	pathway	 Jak/Stat	pathway	
Lomefloxacin	 	 pRIP2..S176	(0.093)	 AKT	(0.020)	PTEN	(0.097)	
P38.MAPK	(0.061)	
phospho.P38.MAPK..	
						T180.Y182	(0.002)	
phospho.JAK2..Tyr221	(0.045)	
phospho.cSrc..T416	(0.079)	
	 	 c.IAP1	(0.091)			 	 c.Raf	(0.060)	ERK1.2	(0.061)	 JAK2	(0.094)	
Cefamandole	
nafate	
	
	 	 PI3K.P110	(0.009)	 	 	
	 	 TRAF2	(0.003)		 AKT	(0.000)	phospho.Bad..S136	(0.087)	phospho.cRaf	(0.047)	 phospho.c.Jun..S63	(0.000)	phospho.MAPKAPK.2..							Thr334...27B7	(0.009)	ERK1.2	(0.044)	phospho.ERK1.2	(0.006)	
STAT3	(0.010)	phospho.JAK2..Tyr221	(0.011)	phospho.cSrc..T416	(0.088)	phospho.ATF.2..Thr71	(0.002)	
Ketoprofen	 	
	
	
	 	 	 SOCS3	(0.012)		
	 	
	
	
	 phospho.PDK1	(0.063)	phospho.cRaf	(0.032)	 phospho.MAPKAPK.2..							Thr334...27B7	(0.006)	phospho.ERK1.2	(0.093)	 phospho.STAT3..Tyr705(0.002)	phospho.cSrc..T416	(0.098)	phospho.ATF.2..Thr71	(0.036)	
Estradiol-3-
sulphate	
	
	 	 	 	 	
	 	
	
	
A20.TNFAIP3(0.076)	 phospho.SAPK.JNK.Thr(0.051)	 	 	
Fosfomycin	
	
	
	 	 	 	 	
	
	
	 pRIP2..S176	(0.001)			 phospho.AKT.Thr	(0.021)	 phospho.Sek1.MKK4..							Thr261	(0.083)	Phospho.MKK3..Ser189							..MKK6..Ser207	(0.053)	ERK1.2	(0.040)	
JAK2	(0.002)	
Methyl-	
prednisolone	
	
	 	 	 	 	
	
	
	
	 	 	 p.HSP27..Ser82	(0.004)	 	
	
	 28	
FIGURE	LEGENDS	
Figure	1.	(A)	Coefficient	of	variation	calculated	for	BCA	protein	yield	and	MTT	cell	viability	for	row,	column	and	entire	96	well	plates	where	SK-Hep-1	cells	have	been	robotically	seeded	at	100,000	cells/well.		Cells	were	seeded,	settled	overnight	at	37oC,	5%	CO2	and	then	exchanged	to	serum-free	medium	for	24	hours,	followed	by	robotic	medium	removal,	washing	and	handling	for	lysis	and	subsequent	BCA/MTT	assay.		A	box	and	whisker	plot	is	shown,	with	median	represented	by	a	black	line	within	the	box	that	represents	the	interquartile	range,	using	Tukey’s	estimation	for	whisker	length.		The	mean	is	represented	by	a	‘+’	symbol.		Outliers	are	plotted	as	black	circles.	(B)	Box	plots,	showing	median	and	interquartile	range	and	whiskers	(Tukey’s	estimation)	of	actin	signal	levels	from	RPPA	analysis	of	triplicated	SK-Hep-1	seeded	plates	(105	cells/well).		Duplicate	array	features	were	printed	per	sample	(well)	onto	separate	arrays	and	probed	for	a	standardly	used	housekeeping	protein	(b-actin)	and	four	alternatives	(a-tubulin,	GAPDH,	NuP98	and	b-catenin).		A	unique	sample	(n=96)	was	used	for	each	experiment.		Mean	CV±SD	of	the	3	replicates	is	shown	above	each	group	of	plots	(AFU,	arbitrary	fluorescence	units).		
(C)	Box	plots,	showing	median	and	interquartile	range	and	whiskers	(Tukey’s	estimation),	of	the	coefficient	of	variation	of	actin	signal	levels	from	RPPA	analysis	of	SK-Hep-1	seeded	plates	(105	cells/well).		Replicate	wells	were	subjected	to	14	different	treatments	but,	for	this	analysis,	the	data	were	used	to	determine	reproducibility	of	printing.		Duplicate	array	features	were	printed	per	sample	(well)	onto	separate	arrays	and	probed	for	b-actin.		For	DMSO	(±)	and	PMA	treatment,	n=16	biological	replicates;	for	all	other	treatments,	n=32	biological	replicates.		CVs	were	calculated	for	each	replicate	group	on	each	array	(n=11).		Both	technical	replicates	for	a	sample	were	excluded	from	analysis	if	one	or	both	were	flagged	for	poor	spot	morphology	or	other	imaging	issues	during	scanning,	or	if	the	actin	signal	for	at	least	one	replicate	was	identified	as	>5.5	SD	away	(±)	from	the	mean	signal	of	the	replicate	set.	(D)	(i)	SK-Hep-1	cells	response	to	100nM	PMA	stimulation	over	1	hour	as	measured	by	increased	phosphorylation	of	HSP-27.		Z’	=	0.368	and	SSMD	b	=	6.68	averaged	for	this	set	of	assays,	n=24	replicates.		(ii)	Upstream	inhibition	of	PMA-induced	ERK1/2	phosphorylation	by	the	MEK1/2	inhibitor	PD98059	(IC50	~	5-10µM).		For	range	QC,	the	Z’	was	calculated	to	be	0.33	and	the	SSMD	b	=	6.16	(N=6).		(E)	Examination	of	the	action	of	three	inhibitors	(applied	at	7	concentrations	followed	by	PMA	stimulation	for	1	hour)	upon	14	intra-cellular	signalling	intermediates.		(i)	PD98059,	a	MEK1/2	inhibitor	(IC50	5-10µM),	showing	expected	effects	on	phosphorylation	of	ERK1/2	(pERK1/2,	green	circles,	SSMD	b	score	=	8.58)	and	effects	on	MEK	1/2	abundance	(orange	squares,	SSMD	b	score	=	4.8).		(ii)	
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FR180204	is	an	ERK1/2	inhibitor	that	does	not	stop	ERK1/2	phosphorylation	and,	as	expected,	shows	no	effect	on	the	molecules	tested.		(iii)	SB203580	is	a	MAPKAPK2	phosphorylation	inhibitor;	however,	an	inhibitory	effect	on	pERK1/2	is	observed	(green	circles,	SSMD	b	score	=	3.81).		All	sample	time	points	are	from	single	well	cultures,	examined	as	7	technical	replicates	on	the	14	arrays	used.	
Figure	2.		(A)	representative	example	of	a	single	array,	printed	using	a	2x4	pin	arrangement.	Not	all	space	on	the	array	is	used	at	this	feature	spacing.	(A)	also	shows	the	dimensions	and	layout	of	the	array.	(B)	an	array	after	probing	and	scanning	for	b-actin	(false-coloured	red)	and	phospho-AKT	(Threonine)	(false-coloured	green)	with	appropriate	antibodies.	Each	chemically	treated	culture	well	is	represented	as	duplicate	features.	The	array	holds	all	three	experimental	replicates	and	all	controls.	 
Figure	3.		Analysis	of	compound	activity	in	screening	of	NINDS	and	Sequoia	compound	libraries	for	effects	on	signalling	molecules	in	C33Y-TNFR1-transfected	SK-Hep-1	cells	compared	to	WT-TNFR1-transfected	SK-Hep-1	cells.	(a)	Cumulative	profile	of	scores	(expressed	as	binned	log10	values)	for	all	drugs	at	all	concentrations:	red	bars	–	10nm;	orange	bars	–	102nm;	yellow	bars	–	103nm;	green	bars	–	104nm.		Lower	scores	(to	the	left	of	the	distribution)	correspond	to	higher	suppressive	effects	on	the	C33Y-TNFR1	signalome.		(b)	Clustering	of	the	screened	library	compounds	into	structural	families	with	the	number	of	compounds	in	each	cluster	(x-axis)	plotted	against	the	mean	logged	score	for	each	cluster	in	suppressing	the	C33Y-TNFR1	signalome	(y-axis).		Lower	scores	correspond	to	cluster	with	higher	suppressive	activity.		Compound	clusters	of	interest	based	on	cluster	size	and	mean	score	are	highlighted.		(c)	Identification	of	compounds	predicted	to	show	suppressive	activity	on	the	C33Y-TNFR1	signalome	from	amongst	untested	compounds	listed	in	ChEMBL	as	being	in	phase	IV	clinical	trials	with	molecular	weights	between	100	and	600;	these	predictions	were	generated	by	the	application	to	the	ChEMBL	data	set	of	a	Bayesian	model	based	on	the	compound	activity	scores	derived	from	screening	the	NINDS	and	Sequoia	libraries	on	SK-HEP-1	TNFR1-tranfectants.		The	ChEMBL	compounds	predicted	to	be	active	are	those	with	a	score	≥10	in	the	Bayesian	model	(which	relates	to	the	probability	of	being	active	in	the	microarray	assay),	and	are:	light	blue	–	quinolones/fluoroquinolones/quinolinones;	dark	blue	–	cephalosporins;	pink	–	estradiols;	orange	–	glucocorticoid	steroids;	red	–	other	steroids.		Compounds	shown	as	inverted	triangles	fail	‘Lipinski’s	rule	of	five’	and	so	are	unlikely	to	serve	as	orally	active	drugs	in	humans.	
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Figure	4.	Summary	of	the	modulatory	effects	of	lomefloxacin	on	pro-inflammatory	signalling	pathways	in	TRAPS	patients’	PBMCs.			The	expression	of	molecules	shown	in	red	was	dose-dependently	down-regulated	by	lomefloxacin,	those	in	green	were	upregulated,	and	those	in	blue	were	unaffected.			 	
	 31	
Figure	1.	
	
	 32	
Figure	2.	
	
	 	
	 33	
Figure	3	
	
	
	 	
	 34	
Figure	4	
	
	
	
	 1	
Appendix	A.		Supplementary	Information	
A	signalome	screening	approach	in	the	autoinflammatory	disease	
TNF	Receptor	Associated	Periodic	Syndrome	(TRAPS)	highlights	
the	anti-inflammatory	properties	of	drugs	for	repurposing	Ian	Todda,1,	Ola	H.	Negma,b,g,1,	Jenna	Repsc,h,		Paul	Radforda,	Grazziela	Figueredoc,	Elizabeth	M.	McDermottd,	Elizabeth	Drewed,	Richard	J.	Powella,	Susan	Bainbridgea,	Mohamed	Hameda,		Sharon	Crouche,	Jon	Garibaldic,	Steve	St-Gallayf,	Lucy	C.	Fairclougha,2,*,	Patrick	J.	Tighea,2	
aSchool	of	Life	Sciences,	The	University	of	Nottingham,	A	Floor	West	Block,	Queen’s	
Medical	Centre,	Nottingham,	NG7	2UH,	UK		
bMedical	Microbiology	and	Immunology	Department,	Faculty	of	Medicine,	Mansoura	
University,	Egypt;		
cAdvanced	Data	Analysis	Centre,	School	of	Computer	Science,	The	University	of	
Nottingham,	Jubilee	Campus,	Nottingham,	NG8	1BB,	UK;		
dNottingham	University	Hospitals	National	Health	Service	Trust,	Queen’s	Medical	
Centre	Campus,	Nottingham,	NG7	2UH,	UK;		
eBusiness	Engagement	and	Innovation	Services,	The	University	of	Nottingham,	Jubilee	
Campus,	Nottingham,	NG8	1BB,	UK;		
fSygnature	Discovery	Limited,	BioCity,	Pennyfoot	Street,	Nottingham,	NG1	1GF,	UK		
Mathematical	data	analysis	methodology	Step	1	1a)	Data	Creation		Considering	1360	drugs,	a	wild	type	sample	and	C33Y	mutation	sample	are	given	the	drug	at	4	different	concentrations.		There	are	also	16	control	wild	type	and	16	C33Y	mutation	samples	given	the	DMSO	solution	at	4	different	concentrations.		This	
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leads	to	11,008	=	[(1360+16)	x	4	x	2]	data	points.	For	each	data	point,	x,	we	have	the	sample	type	(C33Y	or	WT),	the	drug,	the	concentration	of	the	drug	and	the	signals	obtained	via	the	microarray	for	40	various	molecules.	
Let	!"#$% 	correspond	to	molecule	n’s	signal	for	sample	' ∈ {0,1},	drug	. ∈ ℤ01234	and	concentration	5 ∈ ℤ06.		Where	'	=0	when	the	sample	is	a	C33Y	mutation	and	'	=1	when	the	sample	is	a	WT,	.	Î	[1361,1376]	for	the	DMSO	1-16	samples	and	1	to	1360	for	the	other	drug	samples	and	5	is	the	log	to	the	base	10	of	the	samples	drug	concentration.	Then	<% = {!"#$% }	is	the	set	of	all	the	signals	returned	by	the	micro-array	for	molecule	>,	where		> ∈ ℤ06?.		We	calculate	the	distance	between	the	signal	intensities	for	samples	corresponding	to	C33Y	given	drug	'	and	the	samples	corresponding	to	WT	with	no	drug	(.	Î	[1361, 1376])	at	concentration	k	as,	
A"$ = (	!?"$% 	− 	DEA'F> {!1241"$% , !124G"$% , … , !1234"$% } )IJK {!1241"$% , !124G"$% , … , !1234"$% }% 	Where,	for	each	antibody,	this	calculates	the	difference	between	the	signal	for	the	C33Y	given	drug	'	at	concentration	5	minus	the	median	signal	for	the	WT	given	DMSO	at	concentration	5	divided	by	the	inter	quartile	range	(IQR)	of	the	signal	for	the	WT	given	DMSO	at	concentration	5.	This	is	effectively	a	weighted	sum,	where	more	emphasis	is	added	to	the	drug	and	concentration	pairs	that	appear	to	have	less	signal	variance	in	the	wild	type	patients.	The	sum	over	all	the	molecules	gives	the	overall	measure	of	difference	between	the	C33Y	TRAPs	patient	given	drug	'	at	concentration	5	and	the	WT	patient	given	no	drug.		Finally,	we	find	the	best	concentration	for	drug	'	by	finding,	argmin$ {A"$}.	We	then	return	the	rank	of	drug	'	and	concentration	5	in	ascending	order	of	the	measure	A"$ .	Clinical	experts	reviewed	the	ranked	list	and	chose	7	drugs	to	be	investigated	in	more	detail	based	on	the	rank.	How	were	step	1	results	used	to	identify	the	drugs?	
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Step	2	2a)	Data	creation	For	step	2,	as	in	step	1,	we	had	the	40	molecule	signals	at	four	concentrations	of	the	drugs	of	interest.		The	calculations	are	exemplified	here	for	5	C33Y	TRAPs	patients	and	4	WT	healthy	control	subjects	without	the	mutation	for	each	molecule	and	concentration.	2b)	Preprocessing	After	normalizing	the	micro	array	data	we	removed	any	potential	signal	outliers.	For	each	set	of	C33Y	patients	or	each	set	of	WT	patients	we	calculated	the	median	absolute	deviation	(MAD)	for	each	drug	and	concentration	combination.		Any	signal	that	was	three	times	the	MAD	away	from	the	median	signal	of	the	group	was	removed.	2c)	Investigating	interaction	importance	To	model	the	data	(with	outliers	removed),	we	applied	mixed-effect	models	of	the	form:	RST = 	UVW +	YTZT +	[S	ZT	~	] ^,_ 																	[S	~	] ^, `abS 									Where	RST ∈ ℝad	e	f	is	the	signals	observed	for	the	9	patients,	taking	7	different	drugs	at	4	different	concentrations,	UV 	∈ ℝad	e	g	is	the	matrix	of	fixed	effects,	W ∈ℝf	e	g	is	the	vector	of	fixed	effect	coefficients,	h# ∈ ℝi	j	1	is	the	random	effects,	k#	 ∈ℝ 	is	the	random	effects	coefficient	(per	patient	random	effect),		l" 	is	the	252	x	1	vector	of	errors	for	observations,	m	is	the	q	x	q	covariance	matrix	for	the	random	effects	and	nGΛ"is	the	4	x	4	covariance	matrix	for	the	errors.			For	each	drug	and	molecule,	the	two	mixed-effect	models	applied	were,	
• Model	1:		
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RST = Wp +	WaqrstS + WuvswS + Wxyz{yS + W|qrstSvswS +																						W}qrstSyz{yS + W~vswSyz{yS + WdqrstSvswSyz{yS +																					ZT + [S		
• Model	2:		RST = 	Wp +	WaqrstS + WuvswS + Wxyz{yS + W|qrstSyz{yS																								+W}vswSyz{yS + ZT + [S			where	RST	is	the	ith	signal	reading	of	the	molecule	for	patient	j,		qrstS	is	an	indicator	of	whether	the	drug	of	interest	was	given	to	the	patient	j	for	the	ith	signal	reading,	vswS	is	an	indicator	of	whether	the	patient	j	had	the	TRAPs	mutation	and	yz{yS	is	the	log10	of	the	concentration	of	the	drug	given	for	the	ith	signal	reading	of	patient	j.		The	random	effects	term	ZT	means	than	patient	variation	is	included	into	the	models,	with	the	random	effect	coming	from	a	Normal	distribution	with	0	mean.	The	second	equation	excludes	both	the	interaction	between	the	drug	and	mutation	and	the	interaction	between	concentration,	mutation	and	drug.		We	then	applied	a	log	likelihood-ratio	test	to	determine	whether	the	first	model	(including	the	additional	interactions)	significantly	improved	the	model	compared	to	the	second	model	fit	while	accounting	for	the	additional	complexity	of	the	model	with	the	interaction	terms.		We	used	a	significant	level	of	10%	due	to	the	small	number	of	samples	limiting	the	power	of	the	analysis.				2d)	Alleviating	vs	exacerbating	the	difference	In	the	previous	step	we	have	identified	the	drugs	that	potentially	cause	patients	with	the	TRAPs	mutation	to	have	a	different	molecule	signal	dynamic	compared	to	patients	without	the	mutation	and	drug.		However,	this	does	not	tell	us	whether	the	drug	exacerbates	or	alleviates	the	different	in	the	antibody	signal	between	the	patients	with	TRAPs	and	those	without.	We	want	to	find	drugs	that	normalise	the	TRAP’s	mutation	molecule	signals	(e.g.	make	them	representative	of	the	signal	for	wild	type	patients	taking	no	drug).	To	investigate	this,	we	also	calculated	the	fixed	effect	coefficients	for	model	3,	
	 5	
RS = 	W^ + Wpqrst: ÄSvsw: ÄSyz{yS + Waqrst: ÅSvsw: ÄSyz{yS +Wuqrst: ÄSvsw: ÅSyz{yS +	Wxqrst: ÅSvsw: ÅSyz{yS + ZS + [S		
	We	use	model	3	to	determine	whether	the	coefficient	of	the	fixed	effect	corresponding	to	taking	the	drug	when	the	patient	had	the	mutation	(Wp)	was	less	than	the	coefficient	of	the	fixed	effect	corresponding	to	not	taking	the	drug	when	the	patient	did	not	have	the	mutation	(Wx).		Justification	of	this	is	that	the	patients	with	the	mutation	have	an	elevated	signal	for	the	molecules	investigated,	so	if	the	presence	of	the	drug	and	mutation	interaction	is	causing	the	signal	to	decrease	at	a	greater	rate	(or	increase	at	a	slower	rate)	than	the	absence	of	the	drug	and	mutation	interaction	over	concentration,	then	this	suggests	the	TRAPs	patients’	signals	are	normalizing	as	the	drugs	concentration	increases.		2e)	Combining	results	Finally,	we	calculate	the	number	of	molecule	for	each	drug	where	the	likelihood	test	showed	a	significant	interaction	between	the	drug,	concentration	and	mutation	(model	1	fit	the	data	better	than	model	2)	and	the	drug	showed	signs	of	normalizing	the	molecule’s	signal	(coefficient	Wpwas	less	than	Wx	in	model	3).		
